Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder. In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient. The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …
Bipolar disorder is a condition characterized by cyclical mood swings, transitioning from depression to mania (or hypomania). For a period of time, an individual with bipolar disorder will experience debilitating bouts of depression – and often unexpectedly, their entire neurophysiology will shift to facilitate a state of mania (elevated mood). Diagnostically, there are multiple types …
Delusions of grandeur are false beliefs held by an individual in which they believe with full conviction that they are a celebrity, person of high rank, omnipotent, and/or a powerful entity – despite significant evidence to the contrary. Imagine waking up one day thinking that you’re the president of the United States, despite the fact …
Michigan State University (MSU) researchers recently published new data in the journal “Science” providing a first ever look at the crystallized structure of translocator protein (TSPO) (18kDa). Translocator protein is located within the outer portion of the mitochondrial membrane. Its primary function is to transport cholesterol within mitochondria, which then is utilized to produce steroids. TSPO …
Bipolar disorder is characterized by uncontrollable mood swings typically from a depressed state of functioning to either mania or hypomania. Most people with Bipolar disorder tend to have a genetic predisposition to the illness, but even those without a genetic predisposition can develop it. The trend in society among psychiatrists and mental health professionals is …
For years, researchers have been investigating illicit drugs to determine whether they could be used under supervision to treat mental illnesses like depression and bipolar disorder. Although many of these substances have shown promise, in many cases the side effects and addiction potential outweigh any therapeutic benefits. Other times, many drugs may be temporarily helpful …
Latuda (Lurasidone) is a new atypical antipsychotic drug that is approved for the treatment of depressive episodes in bipolar disorder (type 1) as well as schizophrenia. It is considered a relatively new drug as it was just approved in 2013 to treat depressive episodes for people with bipolar I disorder. This drug is somewhat unique …